BRIEF published on 07/24/2024 at 12:35, 1 year 6 months ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Merger Financing Nasdaq Biopharmaceutical QTORIN™
PRESS RELEASE published on 07/24/2024 at 12:30, 1 year 6 months ago Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Palvella Therapeutics, Inc. and Pieris Pharmaceuticals, Inc. announce a merger to focus on rare genetic skin diseases with QTORIN™ rapamycin. Joint webcast on July 24 at 8:30am ET Merger Clinical-stage Genetic Skin Diseases QTORIN™ Rapamycin FDA-approved Therapies
BRIEF published on 04/19/2024 at 18:15, 1 year 9 months ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Reverse Stock Split Nasdaq Compliance Financial Regulation Pieris Pharmaceuticals Stock Adjustment
PRESS RELEASE published on 04/19/2024 at 18:10, 1 year 9 months ago Pieris Pharmaceuticals Announces 1-for-80 Reverse Stock Split Pieris Pharmaceuticals, Inc. announces a 1-for-80 reverse stock split effective on April 22, 2024, to comply with Nasdaq listing requirements. No fractional shares will be issued Reverse Stock Split Compliance Nasdaq Pieris Pharmaceuticals Stockholder Ownership
BRIEF published on 03/27/2024 at 13:05, 1 year 10 months ago Pieris Pharmaceuticals Announces New Strategy to Maximize Financial Potential Shareholder Value Pieris Pharmaceuticals Strategic Reorganization Milestone Payments Royalty Potential
PRESS RELEASE published on 03/27/2024 at 13:00, 1 year 10 months ago Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential Pieris Pharmaceuticals, Inc. announces strategic repositioning to maximize milestone and royalty potential from immuno-oncology assets. Cost-saving measures extend cash runway into 2027 Strategic Repositioning Cost-saving Measures Pieris Pharmaceuticals Milestone Payments Immuno-oncology Assets
Published on 02/06/2026 at 08:00, 1 hour 17 minutes ago Caledonia Mining Corporation Plc Non-Executive Director Shareholding Notification
Published on 02/06/2026 at 00:57, 8 hours 20 minutes ago Noram Lithium Announces Closing of Fully Allocated Non-Brokered Financing
Published on 02/06/2026 at 00:00, 9 hours 17 minutes ago LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Published on 02/05/2026 at 23:15, 10 hours 2 minutes ago Amarc Further Expands Its Toodoggone Technical Team
Published on 02/05/2026 at 23:00, 10 hours 17 minutes ago Grounded People Announces Non-Brokered Private Placement and Strategic Review
Published on 02/06/2026 at 09:00, 16 minutes ago Original-Research: 123fahrschule SE (von NuWays AG): BUY
Published on 02/06/2026 at 08:00, 1 hour 17 minutes ago A stronger and more competitive Ørsted after a defining year with earnings of DKK 25.1 billion within guidance
Published on 02/05/2026 at 18:06, 15 hours 10 minutes ago Aéroports de Paris SA - Shares and voting rights as of 31 January 2026
Published on 02/05/2026 at 18:00, 15 hours 17 minutes ago Information concerning the total number of voting rights and shares in the share capital as of January 30, 2026
